Lexaria Bioscience Corp. - Warrant (LEXXW)

DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects

New patents received for the treatment of epilepsy and for the sublingual delivery of nicotine

Oral DehydraTECH-liraglutide showed a pronounced reduction in adverse events (“AEs”) as compared to injected liraglutide (Saxenda(R))

Biotechnology Sector's Premier Strategic Partnering Event

KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update on corporate developments.

Lexaria executing a triple-pronged strategy in obesity and diabetes

5th study arm in 12-week Phase 1b Study receives lead clinical site approval

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.00 per share (or per pre-funded warrant in lieu thereof) Other than the pre-funded warrants, no other warrants were issued to the institutional investor in the registered direct offering.

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2,000,000 shares of common stock at a purchase price of $1.00 per share in a registered direct offering. The closing of the offering is expected to occur on or about April 28, 2025, subject to the satisfaction of customary closing conditions.

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industry

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide

Pursuing the world's first-ever orally-dosed liraglutide

Additions broaden DehydraTECH patent suite for Epilepsy

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this annual letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders.

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®

Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss

North American drug delivery development experts added to help guide Lexaria's strategic plans

Dr. Gibson joining Lexaria's new scientific advisor board

Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide